Conference abstractPublished 8 Aug 2016
CDA-NABC-cytidine deaminase activity a predictive marker of toxicity/efficacy in nucleosidic analogs-based chemotherapy
Badji-Mokhtar University, Algeria
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Nucleoside analogues such as gemcitabine and cytarabine are widely prescribed in pediatric and adult oncology. However, large variability in clinical outcome and efficacy has been observed. Therefore, new biomarkers with predictive power to assess inter-individuals differences in clinical outcome are urgently warranted. Cytidine Deaminase (CDA) is a liver enzyme that plays a crucial role in the metabolism of nucleoside analogues, coded by a gene displaying several genetic and epigenetic polymorphisms. Consequently, CDA activity is present various phenotypes, ranging from deficient (Poor Metabolizer patients, PM), to ultra-rapid deaminator patients (Ultra-Metabolizer patients, UM), with subsequent impact on drug pharmacokinetics and pharmacodynamics eventually. Several studies showed that CDA status was well correlated with clinical outcomes in patients undergoing nucleosidic analogs-based chemotherapy. Therefore, a low CDA activity is associated with more toxicity but a higher efficacy, while a high activity will lead to a lower efficacy but less toxicity. CDA phenotypic screening and prior stratification of patientsâÂ?Â? status should be considered as relevant strategy to personalize dosing and to improve efficacy/toxicity ratio.
Subjects
Oncology & CancerAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalCancer Science & Therapy
- SubjectOncology & Cancer
- BylineArticles whose byline prints “Adel Gouri”
